Guerbet SA (FRA:4G8)

Market Cap	167.60M -47.9%
Revenue (ttm)	820.92M -2.4%
Net Income	7.74M -76.4%
EPS	0.61 -76.3%
Shares Out	n/a
PE Ratio	21.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	45
Open	12.94
Previous Close	13.34
Day's Range	12.94 - 12.94
52-Week Range	12.90 - 27.70
Beta	n/a
RSI	40.48
Earnings Date	Mar 11, 2026

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a...

• Industry: X-Ray Apparatus and Tubes and Related Irradiation Apparatus
• Founded: 1926
• Employees: 2,842
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4G8

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.